Skip to main content

Table 1

From: High-dose IL-2 in metastatic melanoma: better survival in patients who also received patient-specific autologous tumor cell vaccine

Therapy IL-2 IL-2 + Vaccine
Portion female 58% 59%
Median age at diagnosis 50 yrs 40 yrs
Median age at IL-2 54 yrs 44 yrs
Median age at vaccine N/A 47
Median survival from IL-2 12.8 mos 40.3 mos
5-year survival from IL-2 14% 44%